Retinal Prosthesis Technology Landscape 2026 — PatSnap Insights

Source: https://www.patsnap.com/resources/blog/articles/retinal-prosthesis-patent-landscape-2026/ Published: 2026 (AI-generated patent landscape summary by PatSnap Eureka)

Three Modalities, One Resolution Problem

Retinal prosthesis technology in 2026 divides into three principal sub-domains:

1. Electronic electrostimulation — microelectrode arrays (epiretinal or subretinal), camera-based signal capture, wireless stimulus encoding. Current electrodes: 50–450 µm diameter. Best acuity achieved in dataset: ~20/1400 (well below 20/200 legal blindness threshold). Cornell University EP patent identifies electrode-to-cell size mismatch as the key constraint.
2. Photovoltaic subretinal implants — subretinal photodiode arrays powered by projected NIR/visible light from a headset; each pixel converts light to charge stimulating overlying bipolar cells (no transcutaneous wires). The PRIMA implant (Pixium Vision, Stanford technology) has achieved 20/460–20/565 in AMD patients. Stanford 2023 CN patent analysis: 50 µm pixels needed for 20/200; 25 µm pixel pitch + optical field confinement targets 20/100 or better.
3. Cell-based biological replacement — hESC/iPSC-derived RPE cells to reconstitute the metabolic support layer for surviving photoreceptors. Assignees: Astellas Institute for Regenerative Medicine, Lineage Cell Therapeutics, U.S. Government (NIH).

Key statistics: 20/1400 (best electronic acuity); 20/460 (PRIMA photovoltaic); 25 µm (Stanford target pixel pitch for 20/100); 11 jurisdictions with active filings.

Innovation Timeline (1999–2026)

• 1999/2005: Second Sight Medical Products — Retinal Color Prosthesis (AU); electrode-based electrical stimulation, colour channel differentiation, telemetry.
• 2005: Alan Y. Chow — subretinal MMRI-4 (DE); PiN/NiP photodiode configurations.
• 2012: STMicroelectronics S.R.L. (IT) — foundational retinal prosthesis patents.
• 2013: Cornell University (CN) — neural-encoding prosthesis; targets single cells or small clusters on the same time scale as normal retina.
• 2018: Lineage Cell Therapeutics (WO) — methods for measuring therapeutic effects.
• 2021: Astellas Institute for Regenerative Medicine (TW) — hESC-RPE transplantation.
• 2022: Cornell University (EP) — encoder-based approach; claims robotic/machine vision licensing extension.
• 2023: Stanford University / Board of Trustees of Leland Stanford Junior University (CN) — photovoltaic prosthesis with optical field confinement; pre-charging architecture; 25 µm pixel pitch; targets 20/100 acuity.
• 2023/2025: Notal Vision Ltd. (US) — AI/OCT home monitoring.
• 2024: U.S. Government / NIH (CN) — PLGA scaffold-based RPE implant (20–30 µm thickness, ~1:1 DL-lactide/glycolide, <1 µm pore size, 150–650 nm fiber diameter).
• 2024: Diamentis Inc. (BR) — bidirectional retinal stimulation + spectroscopic data capture.
• 2025: Octant Inc. (WO) — gene therapy for RP.
• 2025: Nightstarx Limited (SG/IL) — gene therapy for RP.
• 2026: Novartis AG (US) — deep learning for geographic atrophy progression prediction.

Assignee Geography (11 Jurisdictions: EP, US, CN, AU, IT, KR, JP, TW, WO, IN, BR)

• Electronic/photovoltaic hardware: concentrated in small number of US academic/startup assignees; key electronic filings in EP, US, CN, AU, IT; photovoltaic concentrated in CN (Stanford) and DE (Chow). White spaces: US, EP, JP, KR for next-gen photovoltaic architectures.
• Cell-based RPE: broadest multi-jurisdictional prosecution (TW, AU, US, WO, CN, JP) — Lineage Cell Therapeutics holds AU, US, WO, BR, JP.
• Diagnostic/AI monitoring: most distributed (6 distinct assignees): Notal Vision, Roche, Novartis, Genentech, EPFL, Magic Leap — predominantly US and JP grants.

Five Emerging Directions (2023–2026)

1. Optical field confinement (Stanford CN 2023): Pre-charging pixels that will go dark in the next frame act as transient local return electrodes, reducing inter-electrode crosstalk and improving contrast. Targets 20/100+ via 25 µm pixel pitch.
2. Scaffold-engineered RPE patches (NIH CN 2024): PLGA scaffold with highly specific parameters (20–30 µm thick, ~1:1 DL-lactide/glycolide ratio, <1 µm average pore size, 150–650 nm fiber diameter) for polarized RPE cell delivery — structured tissue-replacement vs. cell suspension injection.
3. AI-enabled remote retinal monitoring: Notal Vision (US 2023, 2025) — daily home OCT monitoring + algorithmic treatment scheduling. Also Novartis (US 2026), Roche (US 2022), EPFL (JP 2025). Creates an “IP thicket” around post-implant monitoring.
4. Bidirectional stimulation + spectroscopy (Diamentis BR 2024): Exposes retina to controlled light flashes and records resulting spectral response — real-time calibration of prosthetic stimulation parameters; closed-loop architecture.
5. Gene therapy convergence: Octant Inc. (WO 2025) and Nightstarx Limited (SG/IL 2021) — gene-therapy-mediated RP restoration. Positioned as complement, not competitor, to prosthetics: gene therapy preserves residual photoreceptors while prosthetics serve fully-degenerated cases.

Strategic Notes

• Cornell EP patent explicitly extends retinal encoding architecture to “robotic or other mechanical devices where processing of visual information is required” — potential neuromorphic computing licensing.
• Cell-based RPE approaches entering manufacturing-definition phase (Astellas, Lineage, NIH now filing on specific cell purity, scaffold geometry, transplantation parameters) — FTO constraints tightening around PLGA formulations.
• Resolution gap remains central technical barrier; pixel miniaturisation below 25 µm and inter-electrode crosstalk suppression are primary R&D pathways.
• Multi-modal convergence (gene + cell + electronic) requires cross-domain FTO mapping.

Patent References (PatSnap Eureka dataset)

1. Cornell University — Retina Prosthesis, EP 2022
2. Cornell University — Retinal Prosthesis, CN 2013
3. Leland Stanford Junior University — Photovoltaic Retinal Prosthesis with Optically Configurable Electric Field Confinement, CN 2023
4. Second Sight Medical Products — Retinal Color Prosthesis, AU 2005/2006
5. Alan Y. Chow — Retinal Implant Made of Multiphase Microphotodiodes, DE 2005
6. STMicroelectronics S.R.L. — Retinal Prosthesis, IT 2012
7. I-Lumen Scientific Inc. — Electrode Systems and Methods for Vision Treatment, KR 2023
8. Diamentis Inc. — Systems and Methods for Retinal Stimulation/Collection of Retinal Signal Data, BR 2024
9. Astellas Institute for Regenerative Medicine — Pharmaceutical Preparations of Human RPE Cells, TW 2023
10. U.S. Government (HHS/NIH) — Biodegradable Tissue Replacement Implant, CN 2024
11. Lineage Cell Therapeutics — Methods for Measuring Therapeutic Effects of Retinal Disease Therapies, AU 2019
12. Notal Vision Ltd. — OCT Guided Therapy, US 2023 & 2025
13. Octant Inc. — Compositions and Methods for Treating Retinitis Pigmentosa, WO 2025
14. Nightstarx Limited — Compositions and Methods for Treating Retinitis Pigmentosa, SG 2021
15. Novartis AG — Computerized Systems for Prediction of Geographic Atrophy Progression (Deep Learning), US 2026
16. Hoffman-La Roche Inc. — Machine-Learning Techniques for Prediction of Future Visual Acuity, US 2022
17. EPFL — Multimodal Retinal Imaging Platform, JP 2025